Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arpida files iclaprim in Canada

This article was originally published in Scrip

Executive Summary

Arpidahas filed its lead product, the intravenous antibiotic iclaprim, for approval in Canada. The filing is for the treatment of complicated skin and skin structure infection (cSSSI) and includes data from the ASSIST-1 and ASSIST-2 Phase III trials, which showed iclaprim was non-inferior to Pfizer's Zyvox (linezolid) for cSSSI in a group of patients with a high incidence of meticillin-resistant Staphylococcus aureus (MRSA). Iclaprim is a synthetic diaminopyrimidine and Arpida has said it believes the compound may have benefits over Zyvox, an oxazolidinone antibiotic which can cause myelosuppression. The company filed for approval of iclaprim in the US in March and in the EU in July (Scrip Online, March 20th, 2008 and Scrip Online, July 29th, 2008, respectively).

You may also be interested in...



Targacept/AstraZeneca Alzheimer's hope fails in Phase II

Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.

Amgen reveals more details of denosumab's fracture benefit

Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.

GSK and Xenoport file restless legs drug Solzira in US

GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel